These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9783412)

  • 61. Construction and characterization of a thyA mutant derived from cholera vaccine candidate IEM101.
    Yu F; Qi G; Liu Y; Gao S; Kan B
    Mol Biotechnol; 2005 Mar; 29(3):191-6. PubMed ID: 15767696
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cholera: recent updates.
    Weil AA; Ryan ET
    Curr Opin Infect Dis; 2018 Oct; 31(5):455-461. PubMed ID: 30048254
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A new oral vaccine candidate based on the microencapsulation by spray-drying of inactivated Vibrio cholerae.
    Año G; Esquisabel A; Pastor M; Talavera A; Cedré B; Fernández S; Sifontes S; Aranguren Y; Falero G; García L; Solís RL; Pedraz JL
    Vaccine; 2011 Aug; 29(34):5758-64. PubMed ID: 21683110
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge.
    Tacket CO; Losonsky G; Nataro JP; Comstock L; Michalski J; Edelman R; Kaper JB; Levine MM
    J Infect Dis; 1995 Sep; 172(3):883-6. PubMed ID: 7658089
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Determination of Vibrio antibody titers during anti-cholera vaccination].
    Dirimci OT; Cinar V
    Turk Hij Tecr Biyol Derg (1961); 1973; 33(2-3):118-28. PubMed ID: 4807572
    [No Abstract]   [Full Text] [Related]  

  • 66. An oral cholera vaccine for travelers (Vaxchora).
    Med Lett Drugs Ther; 2016 Aug; 58(1502):113-4. PubMed ID: 27552209
    [No Abstract]   [Full Text] [Related]  

  • 67. Current status of cholera and rise of novel mucosal vaccine.
    Yamamoto T
    Jpn J Infect Dis; 2000 Oct; 53(5):181-8. PubMed ID: 11135702
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Attenuated recombinant strains of Vibrio cholerae for oral immunization.
    Srivastava BS; Sinha VB; Srivastava R
    Bull World Health Organ; 1979; 57(4):649-54. PubMed ID: 316742
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunoglobulins in bile and serum of the rabbit associated with protection after Vibrio cholerae infection and vaccination.
    Rijpkema SG; Jansen WH; Gielen H; Guinée PA
    Microb Pathog; 1987 Nov; 3(5):365-75. PubMed ID: 2462153
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase.
    Stewart-Tull DE; Lucas C; Bleakley CR
    Vaccine; 2004 Jun; 22(17-18):2137-45. PubMed ID: 15149770
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Construction of a recombinant live oral vaccine from a non-toxigenic strain of Vibrio cholerae O1 serotype inaba biotype E1 Tor and assessment of its reactogenicity and immunogenicity in the rabbit model.
    Thungapathra M; Sharma C; Gupta N; Ghosh RK; Mukhopadhyay A; Koley H; Nair GB; Ghosh A
    Immunol Lett; 1999 Jun; 68(2-3):219-27. PubMed ID: 10424424
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Oral cholera vaccines: use in clinical practice.
    Hill DR; Ford L; Lalloo DG
    Lancet Infect Dis; 2006 Jun; 6(6):361-73. PubMed ID: 16728322
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [The characteristics of the protectiveness of a preparation of Vibrio cholerae outer membrane based on the data from a study using the ligated intestinal loop].
    Urbanovich LIa; Sappo SG; Kolesnik RS; Golubinskiĭ EP; Markov EIu; Ganin VS; Ivanova TA
    Zh Mikrobiol Epidemiol Immunobiol; 1997; (2):43-6. PubMed ID: 9245140
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Emergence of a new cholera pandemic: molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype.
    Waldor MK; Mekalanos JJ
    J Infect Dis; 1994 Aug; 170(2):278-83. PubMed ID: 8035010
    [TBL] [Abstract][Full Text] [Related]  

  • 76. IEM101, a naturally attenuated Vibrio cholerae strain as carrier for genetically detoxified derivatives of cholera toxin.
    Fontana MR; Monaci E; Yanqing L; Guoming Q; Duan G; Rappuoli R; Pizza M
    Vaccine; 2000 Aug; 19(1):75-85. PubMed ID: 10924789
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Intestinal colonization of the infant mouse model by attenuated and virulent Vibrio cholerae strains.
    Cedré Marrero B; García Imia LG; García Sánchez HM; Fariñas Medina M; Talavera Coronel A; Infante Bourzac JF
    Arch Med Res; 1998; 29(3):231-4. PubMed ID: 9775456
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Kinetics of the vibriocidal antibody response to live oral cholera vaccines.
    Wasserman SS; Losonsky GA; Noriega F; Tacket CO; Castañeda E; Levine MM
    Vaccine; 1994 Aug; 12(11):1000-3. PubMed ID: 7975839
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Vibrio cholerae infection and acquired immunity in an adult rabbit model.
    Guinée PA; Jansen WH; Peters PW
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Feb; 259(1):118-31. PubMed ID: 4002931
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Investigation into immunological responses against a native recombinant CTB whole-cell Vibrio cholerae vaccine in a rabbit model.
    Boustanshenas M; Bakhshi B; Ghorbani M
    J Appl Microbiol; 2013 Feb; 114(2):509-15. PubMed ID: 23082752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.